Bristol Myers Squibb's Augtyro receives US FDA approval to treat NTRK─positive locally advanced or metastatic solid ...
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Augtyro (repotrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a …